EYP-1901 intravitreal implant shows effective, stable outcomes in wet AMD at 8 months
Click Here to Manage Email Alerts
BARCELONA, Spain — A subgroup analysis of the DAVIO 2 trial showed that eyes implanted with the EYP-1901 intravitreal insert maintained stable visual acuity with strong anatomic control over 8 months, according to a presenter.
“EYP-1901 (EyePoint Pharmaceuticals) is a combination of vorolanib, which is a potent tyrosine kinase receptor inhibitor, and Durasert E, which is a bioerodible device that allows release of the drug for at least 6 months,” Giovanni Staurenghi, MD, said at the Euretina congress.
Image: Adobe Stock
The trial compared EYP-1901 vs. aflibercept in patients with wet age-related macular degeneration who had previously shown response to anti-VEGF treatment.
At 8 months, there was no difference in best corrected visual acuity change and central retinal thickness change between the two groups. Two-thirds of the eyes implanted with EYP-1901 did not receive a supplemental injection. Staurenghi specified that supplemental injections in the eyes that required them “did not drive best corrected visual acuity outcomes.”
Baseline characteristics, in terms of visual acuity, time from diagnosis and number of previously received injections, did not meaningfully influence visual acuity and anatomical outcomes.
No ocular or systemic adverse events were observed.
“I showed the 8-month data, but these are also the 12-month results of best corrected visual acuity change, and you see that there is no difference between 8 and 12 months — meaning that the effect of the drug is probably still there,” Staurenghi said.
The phase 3 LUGANO and LUCIA studies will be starting soon, he said.
Collapse
Staurenghi G, et al. Subgroup analysis from the DAVIO 2 trial, a phase 2, multicenter study of a single injection of EYP-1901 (vorolanib intravitreal insert) vs aflibercept for previously treated wet age-related macular degeneration. Presented at: Euretina congress; Sept. 19-22, 2024; Barcelona, Spain.
Read more about
Click Here to Manage Email Alerts